Dashboard
Manage Tickers

OCGN Ocugen, Inc.

Nasdaq ocugen.com


$ 1.51 $ -0.06 (-3.82 %)    

Wednesday, 22-Oct-2025 18:25:20 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.27 $ -5.89 (-0.96 %)
DIA $ 464.98 $ -3.44 (-0.73 %)
SPY $ 666.76 $ -3.49 (-0.52 %)
TLT $ 92.19 $ 0.06 (0.07 %)
GLD $ 376.01 $ 0.04 (0.01 %)
$ 1.51
$ 1.53
$ 1.45 x 2,125
$ 1.55 x 5
-- - --
$ 0.52 - $ 1.90
4,449,954
na
441.38M
$ 2.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-04-2025 06-30-2025 10-Q
2 05-09-2025 03-31-2025 10-Q
3 03-05-2025 01-01-1970 10-K
4 11-14-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-14-2024 03-31-2024 10-Q
7 04-16-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-21-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-28-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-05-2022 06-30-2022 10-Q
14 05-06-2022 03-31-2022 10-Q
15 02-28-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-06-2021 06-30-2021 10-Q
18 05-07-2021 03-31-2021 10-Q
19 03-19-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-14-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 03-27-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-09-2019 06-30-2019 10-Q
26 05-15-2019 03-31-2019 10-Q
27 03-22-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-09-2018 06-30-2018 10-Q
30 05-10-2018 03-31-2018 10-Q
31 03-15-2018 12-31-2017 10-K
32 11-09-2017 09-30-2017 10-Q
33 08-10-2017 06-30-2017 10-Q
34 05-11-2017 03-31-2017 10-Q
35 03-16-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-11-2016 06-30-2016 10-Q
38 05-12-2016 03-31-2016 10-Q
39 03-10-2016 12-31-2015 10-K
40 11-12-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

forecasting-the-future-4-analyst-projections-for-ocugen
Forecasting The Future: 4 Analyst Projecti...
09/19/2025 12:01:52

on-sept-16-carisma-terminates-merger-agreement-with-ocugen
On Sept 16, Carisma Terminates Merger Agre...
09/18/2025 15:14:41

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/17/2025 21:06:24

ocugen-shares-are-trading-higher-monday-whats-going-on
Ocugen Shares Are Trading Higher Monday: W...
09/15/2025 20:29:16

Ocugen shares are trading higher Monday after the company announced a licensing agreement with Kwangdong Pharmaceutical for the...

ocugen-strikes-75m-licensing-deal-giving-kwangdong-exclusive-korean-rights-to-gene-therapy-for-blindness
Ocugen Strikes $7.5M Licensing Deal Giving...
09/15/2025 10:10:53

Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for...

Core News & Articles
Carisma Therapeutics To Receive $5M Invest...
08/29/2025 20:26:43

 

the-committee-for-medicinal-products-for-human-use-of-the-european-medicines-agency-reviewed-the-study-design-endpoints-and-planned-statistical-analysis-of-ocugens-ongoing-ocu410st-phase-23-gardian3-trial-for-stargardt-disease-and-provided-acceptability-of-a-single-us-based-trial-for-submission-of-a-marketing-authorization-application
The Committee For Medicinal Products For H...
08/13/2025 10:29:45

With enrollment scheduled to be complete in the first quarter of 2026 the Company remains on track for a BLA filing in the firs...

ocugen-announces-20m-direct-offering-of-20m-shares-and-20m-warrants-at-a-combined-price-of-100
Ocugen Announces $20M Direct Offering Of 2...
08/08/2025 21:07:37

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases,...

demystifying-ocugen-insights-from-5-analyst-reviews
Demystifying Ocugen: Insights From 5 Analy...
08/04/2025 13:03:05

chardan-capital-maintains-buy-on-ocugen-maintains-7-price-target
Chardan Capital Maintains Buy on Ocugen, M...
08/04/2025 11:16:28

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.

ocugen-q2-eps-005-beats-006-estimate-sales-1373m-beat-350000k-estimate
Ocugen Q2 EPS $(0.05) Beats $(0.06) Estima...
08/01/2025 13:54:09

Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 19....

Core News & Articles
Earnings Scheduled For August 1, 2025
08/01/2025 08:32:17

a-peek-at-ocugens-future-earnings
A Peek at Ocugen's Future Earnings
07/31/2025 18:01:19

us-court-granted-ocugens-motion-to-dismiss-securities-class-action-lawsuit
U.S. Court Granted Ocugen's Motion To Dism...
07/30/2025 21:13:44

-SEC Filing

ocugen-reports-first-patient-dosed-in-phase-23-gardian3-clinical-trial-for-ocu410st-modifier-gene-therapy-candidate-being-developed-for-all-stargardt-disease
Ocugen Reports First Patient Dosed In Phas...
07/18/2025 11:03:45

Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases,...

chardan-capital-maintains-buy-on-ocugen-maintains-7-price-target
Chardan Capital Maintains Buy on Ocugen, M...
06/24/2025 12:03:08

Chardan Capital analyst Daniil Gataulin maintains Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price target.

hc-wainwright--co-reiterates-buy-on-ocugen-maintains-7-price-target
HC Wainwright & Co. Reiterates Buy on Ocug...
06/24/2025 10:54:28

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Ocugen (NASDAQ:OCGN) with a Buy and maintains $7 price tar...

ocugen-ocgn-shares-slide-following-merger-agreement-whats-going-on
Ocugen (OCGN) Shares Slide Following Merge...
06/23/2025 18:26:09

Shares of Ocugen are trading lower Monday afternoon. The company earlier announced a definitive agreement to merge its subsidia...

Core News & Articles
Carisma Therapeutics And Ocugen Subsidiary...
06/23/2025 11:42:46

ocugen-ocgn-stock-soars-on-fda-clearance-for-pivotal-stargardt-disease-trial
Ocugen (OCGN) Stock Soars On FDA Clearance...
06/16/2025 14:58:45

Ocugen's gene therapy for Stargardt disease is now advancing to a pivotal trial. The company's treatment could help pat...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION